Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Inclusion Criteria: * Subjects must be willing and able to provide informed consent * Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1 at enrollment and within 7 days of initiating lymphodepleting chemotherapy * Subjects must have an area of tumor amenable to excisional biopsy (core biopsies may be allowed) for the generation of TIL separate from, and in addition to, a target lesion to be used for response assessment * Any prior therapy directed at the malignant tumor, including radiation therapy, chemotherapy, and biologic/targeted agents must be discontinued at least 28 days prior to tumor resection for preparing TIL therapy * Absolute neutrophil count (ANC) \>= 1000/mm\^3 (within 7 days of enrollment) * Hemoglobin \>= 9.0 g/dL (transfusion allowed) (within 7 days of enrollment) * Platelet count \>= 100,000/mm\^3 (within 7 days of enrollment) * Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) and aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) \< 2.5 x the upper limit of normal (ULN) * Patients with liver metastases may have liver function test \[LFT\] =\< 5.0 x ULN (within 7 days of enrollment) * Calculated creatinine clearance (Cockcroft-Gault) \>= 50.0 mL/min (within 7 days of enrollment) * Total bilirubin =\< 1.5 x ULN (within 7 days of enrollment) * Prothrombin time (PT) \& activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (correction with vitamin K allowed) unless su…